Go Deep
Panacea Biotec Limited
Panacea Biotec Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,360 | -308.3 | 2.62 | 0.03 | 357.60 |
| Oct 2026 | 22,624 | -297.6 | 2.53 | 0.03 | 345.25 |
Panacea Biotec Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,995,700,000.0 | 1,667,500,000.0 | 1,651,900,000.0 | 1,411,300,000.0 |
| Net Profit | 23,000,000.0 | 5,200,000.0 | 39,800,000.0 | -139,200,000.0 |
| EPS | 0.4 | 0.1 | 0.7 | -2.3 |
Panacea Biotec Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 6,099,670,000.0 | 4,926,000,000.0 | 5,519,290,000.0 | 4,569,190,000.0 | — |
| Net Profit | -53,770,000.0 | -83,700,000.0 | -11,730,000.0 | -332,370,000.0 | — |
| EPS | -0.9 | -1.4 | -0.2 | -5.4 | — |
Panacea Biotec Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 12,621,770,000.0 | 12,897,460,000.0 | 12,408,210,000.0 | 12,711,660,000.0 | — |
| Total Liabilities | 4,332,980,000.0 | 4,591,300,000.0 | 4,025,960,000.0 | 4,310,520,000.0 | — |
| Total Equity | 8,348,350,000.0 | 8,347,860,000.0 | 8,420,460,000.0 | 8,436,030,000.0 | — |
Owes vs Owns
Panacea Biotec Limited owed ₹0.34 for every ₹1 it owned in Mar 2026, about the same as ₹0.34 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.34× | 0.36× | 0.32× | 0.34× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Panacea Biotec Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 10.1%Receivables 5.8%Inventory 15.3%Fixed assets (tangible) 51.8%Intangible assets 4.0%Long-term investments 0.6%Other assets 12.4%
How it's funded — Mar 2026
Long-term debt 1.2%Payables 15.0%Other liabilities 18.1%Shareholders' equity 65.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 126.9 | 122.9 | 173.8 | 213.0 |
| Receivables | 73.5 | 72.6 | 57.4 | 60.1 |
| Inventory | 192.8 | 213.7 | 177.9 | 202.1 |
| Fixed assets (tangible) | 654.4 | 640.8 | 636.3 | 623.3 |
| Intangible assets | 50.9 | 42.3 | 36.0 | 25.9 |
| Long-term investments | 7.5 | 3.1 | 1.0 | 3.7 |
| Other assets | 156.1 | 194.5 | 158.3 | 142.9 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.1 |
| Long-term debt | 15.0 | 15.0 | 15.0 | 20.2 |
| Payables | 189.6 | 225.8 | 145.6 | 177.3 |
| Other liabilities | 228.7 | 218.4 | 242.0 | 233.5 |
| Shareholders' equity | 828.9 | 830.6 | 838.2 | 840.1 |
| Net tangible assets | 783.9 | 792.5 | 806.0 | 817.7 |
Panacea Biotec Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 166,940,000.0 | -273,690,000.0 | 34,680,000.0 | -4,224,520,000.0 | — |
| Investing Activities | -404,950,000.0 | 649,840,000.0 | 66,590,000.0 | 4,303,310,000.0 | — |
| Financing Activities | -10,560,000.0 | -26,640,000.0 | -28,080,000.0 | -183,730,000.0 | — |